Antihypertensive Effects of Statins: A Meta-Analysis of Prospective Controlled Studies
Article first published online: 7 MAR 2013
© 2013 Wiley Periodicals, Inc
The Journal of Clinical Hypertension
Volume 15, Issue 5, pages 310–320, May 2013
How to Cite
J Clin Hypertens (Greenwich). 2013;15:310–320. ©2013 Wiley Periodicals, Inc.
- Issue published online: 24 APR 2013
- Article first published online: 7 MAR 2013
- Manuscript Accepted: 18 JAN 2013
- Manuscript Revised: 13 JAN 2013
- Manuscript Received: 16 NOV 2012
In experimental studies, statins have been shown to lower blood pressure through increased nitric oxide bioavailability and improved arterial compliance. The clinical significance of this effect remains poorly documented. The authors performed a meta-analysis of the effect of statins on systolic blood pressure (SBP) and diastolic blood pressure (DBP) including prospective randomized, controlled trials of statin therapy. EMBASE and MEDLINE searches for studies in which patients were randomized to treatment with a statin plus standard treatment (or placebo) vs standard treatment (or placebo) were conducted. Studies that provided data on SBP and DBP values before the initiation of the treatment and at the end of the follow-up period were included. A total of 40 studies with 51 comparison groups examining 22,511 controls and 22,602 patients taking statins were examined. Mean SBP in the statin group decreased by 2.62 mm Hg (95% confidence interval [CI], −3.41 to −1.84; P<.001) and DBP by 0.94 mm Hg (95% CI, −1.31 to −0.57; P<.001). In studies including hypertensive patients, the decrease in blood pressures with statins was slightly greater (SBP, −3.07 mm Hg; 95% CI, −4.00 to −2.15 and DBP, 1.04; 95% CI, −1.47 to −0.61). Similarly, statins effectively reduced SBP in diabetic patients. In this large meta-analysis of prospective controlled studies, the authors found a small but statistically significant reduction of SBP in patients taking statins. The decrease in blood pressure may contribute to the pleiotropic effect of statins in reducing cardiovascular risk.